Stock ALVO ALVOTECH
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Alvotech

Equities

ALVO

LU2458332611

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-06-04 pm EDT 		5-day change 1st Jan Change
13.95 USD +0.29% Intraday chart for Alvotech +1.31% +21.52%
May. 24 Barclays Adjusts Price Target on Alvotech to $22 From $20, Maintains Overweight Rating MT
May. 22 Transcript : Alvotech, Q1 2024 Earnings Call, May 22, 2024

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alvotech Raises Revenue Guidance for the Full Year 2024
CI
Alvotech Narrows Q1 Loss as Revenue Increases; Shares Head Higher Premarket
MT
Alvotech Narrows Q1 Loss as Revenue Increases
MT
Alvotech Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Alvotech Signs Commercialization Deal for Prolia, Xgeva Biosimilar
MT
Alvotech and Dr. Reddy's Partner to Commercialize Biosimilar Candidate Denosumab
MT
Alvotech and Dr. Reddy's Enter into Collaboration for Commercialization of AVT03
CI
Teva Pharmaceutical Industries Limited and Alvotech Announce SIMLANDI® Injection Now Available in the U.S
CI
Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals
MT
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent
MT
Alvotech Announces U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira
CI
Cigna to offer Humira rivals with $0 copay at specialty pharmacy
RE
Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi
CI
Sector Update: Health Care Stocks Advance Late Afternoon
MT
Sector Update: Health Care Stocks Rise Friday Afternoon
MT
Sector Update: Health Care
MT
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US
MT
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US
MT
Alvotech Signs U.S. Agreement to Expand Access for Newly Approved High-Concentration Interchangeable Biosimilar to Humira®
CI
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALVO Stock
  4. News Alvotech
  5. Highlights